Lyudmila Bazhenova, MD of the University of California, San Diego discusses management of EGFR-resistant disease and T790M mutations. Management of patients with EGFR mutant lung cancer who has progressed on EGFR TKI. The most important thing to understand is, upon progression, you need to find if the patient has T790 M resistant mutation. If the patient has a T790M resistant mutation, the data favors very strongly with the use of osimertinib, which is a third generation EGFR TKI. Based on a randomized trial, AURA 3, osimertinib has shown improvement in both the response rate and PFS over platinum-based chemotherapy.
Managing EGFR-Resistant Disease T790 and Beyond
